<!DOCTYPE html SYSTEM "about:legacy-compat">
<html class="no-js">
  <head>
    <meta charset="utf-8"/>
    <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
    <title>D.C. Law Library - D.C. Act 22-617. Opioid Overdose Treatment and Prevention Omnibus Act of 2018.</title>
    <meta property="st:title" content="D.C. Act 22-617. Opioid Overdose Treatment and Prevention Omnibus Act of 2018."/>
    <meta name="description" content="Browse the laws and code of the District of Columbia"/>
    <meta name="viewport" content="width=device-width"/>
    <link href="https://fonts.googleapis.com/css?family=Open+Sans:400italic,700italic,400,700" rel="stylesheet" type="text/css"/>
    <link rel="stylesheet" type="text/css" href="/css/main.css" media="screen"/>
    <link rel="stylesheet" type="text/css" href="/css/print.css" media="print"/>
    <script type="text/javascript">
        var _paq = _paq || [];
        _paq.push(['trackPageView']);
        _paq.push(['enableLinkTracking']);
        (function() {
            var u="//analytics.code.dccouncil.us/";
            _paq.push(['setTrackerUrl', u+'piwik.php']);
            _paq.push(['setSiteId', 1]);
            var d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0];
            g.type='text/javascript'; g.async=true; g.defer=true; g.src=u+'piwik.js'; s.parentNode.insertBefore(g,s);
        })();
        
        window.searchHost = 'https://search.code.dccouncil.us';
        window.queryUrl = '/v1/search';
    </script>
    <noscript>
      <p>
        <img src="//analytics.code.dccouncil.us/piwik.php?idsite=1" style="border:0;" alt=""/>
      </p>
    </noscript>
  </head>
  <body>
    <header>
      <section class="container">
        <a href="http://dccouncil.us">
          <img src="/css/header_logo.png" alt="DC Seal" class="header_logo"/>
        </a>
        <h1 id="sitename">
          <a href="/dc/council/acts/22-617.html">D.C. Act 22-617. Opioid Overdose Treatment and Prevention Omnibus Act of 2018.</a>
        </h1>
        <div class="right no-print search" id="search"> </div>
      </section>
    </header>
    <main class="main container">
      <div class="clearfix" style="width: 100%;">
        <aside id="sidebar" class="col3 quiet">
          <h2>You Are Here</h2>
          <ul class="ancestors">
            <li data-search-path="library|D.C. Code" data-search-heading="D.C. Code" data-search-default="true"/>
            <li data-search-path="library" data-search-heading="All Documents">↪ <a href="/">D.C. Law Library</a></li>
            <li data-search-path="library|dclaws" data-search-heading="D.C. Laws">↪ <a href="/dclaws/">D.C. Laws Codified in the D.C. Code</a></li>
            <li data-search-path="library|dclaws|22" data-search-heading="">↪ <a href="/dclaws/22/">Council Period 22</a></li>
            <li data-search-path="library|dclaws|22|permanent" data-search-heading="">↪ <a href="/dclaws/22/permanent/">Permanent Laws</a></li>
            <li data-search-path="library|dclaws|22|permanent|pending" data-search-heading="">↪ <a href="/dclaws/22/permanent/pending/">Acts pending congressional review</a></li>
            <li data-search-path="library|dclaws|22|permanent|pending|D.C. Act 22-617" data-search-heading="D.C. Act 22-617">↪ D.C. Act 22-617. Opioid Overdose Treatment and Prevention Omnibus Act of 2018.</li>
          </ul>
          <div class="document-info">
            <h2>Law Information</h2>
            <dl>
              <dt>Cites</dt>
              <dd>D.C. Act 22-617 (<a class="internal-link" href="http://lims.dccouncil.us/Download/38775/B22-0459-SignedAct.pdf">PDF</a>)<br/>66 DCR 1656<br/></dd>
              <dt>Effective</dt>
              <dd>Apr. 11, 2019 (Projected)</dd>
              <dt>Legislative History (<a href="http://lims.dccouncil.us/Legislation/B22-0459">LIMS</a>)</dt>
            </dl>
          </div>
          <section class="cta">
            <p>
              <a href="mailto:code@dccouncil.us?subject=[ERROR]+/dc/council/acts/22-617.html">Report Error</a>
            </p>
            <p>
              <a href="mailto:code@dccouncil.us?subject=[FEEDBACK]+/dc/council/acts/22-617.html">Website Feedback</a>
            </p>
            <p>We cannot respond to questions regarding the law.</p>
          </section>
        </aside>
        <section class="col8 body">
          <section class="pending_notice">
        This act is <strong>not yet codified</strong> in the D.C. Code because it is not yet effective as law. It is projected to become effective on Apr. 11, 2019.
      </section>
          <h1 id="/dc/council/acts/22-617.html">D.C. Act 22-617. Opioid Overdose Treatment and Prevention Omnibus Act of 2018.</h1>
          <section class="content">
            <p style="text-align: center;">AN ACT</p>
            <p style="font-style: italic">To expand patient access to opioid use disorder treatment; to require the Department of Health Care Finance and the Department of Insurance, Securities, and Banking to undertake a study to determine the feasibility of expanding opioid use disorder medication offerings in the District; to require hospitals to develop protocols for identifying, treating, discharging, and referring patients with opioid use disorder; to require the Department of Corrections to ensure that individuals who receive treatment for opioid addiction prior to entering a Department of Corrections facility continue to receive that treatment; to amend Title 25 of the District of Columbia Official Code to remove possession of certain drug paraphernalia for personal use as grounds for denial of a license; to amend Title 47 of the District of Columbia Official Code to remove possession of certain drug paraphernalia for personal use as grounds for denial of a license; to amend the Drug Paraphernalia Act of 1982 to permit persons testing personal use quantities of a controlled substance to use, or possess with the intent to use, testing equipment or other objects used, intended for use, or designed for use in identifying or analyzing the strength, effectiveness, or purity of a controlled substance, and to permit community-based organizations to deliver or sell, or possess with the intent to deliver or sell, testing equipment or other objects used, intended for use, or designed for use for that same purpose; and to amend the District of Columbia Appropriations Act of 2001 to remove the prohibition on the operation of needle exchange programs within 1,000 feet of a public or private elementary or secondary school; to amend an Act to relieve physicians of liability for negligent medical treatment at the scene of an accident in the District of Columbia to allow physicians licensed to practice medicine to prescribe, and pharmacists licensed to practice pharmacy, to dispense or distribute, an opioid antagonist; to amend the Prescription Drug Monitoring Program Act of 2013 to require the mandatory registration of prescribers and dispensers, including new licensees, by March 31, 2019.</p>
            <p>BE IT ENACTED BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, That this act may be cited as the "Opioid Overdose Treatment and Prevention Omnibus Act of 2018".</p>
            <p class="marginalia">New Chapter 32 of Title 7</p>
            <h1>TITLE I. OPIOID USE DISORDER TREATMENT</h1>
            <p class="marginalia">New § 7-3201</p>
            <p id="&#xA7;101"><span class="level-num">Sec. 101. </span>Definitions.</p>
            <p>For the purposes of <code-cite doc="D.C. Code" path="7|32">this act</code-cite>, the term:</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;101(1)">(1)</span> "DBH" means the Department of Behavioral Health.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;101(2)">(2)</span> "DHCF" means the Department of Health Care Finance.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;101(3)">(3)</span> "DISB" means the Department of Insurance, Securities, and Banking.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;101(4)">(4)</span> "DOC" means the Department of Corrections.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;101(5)">(5)</span> "DOH" means the Department of Health.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;101(6)">(6)</span> "Health care provider" means a physician, advance practice registered nurse, clinic, hospital, DBH-certified provider organizations, or neighborhood health center, licensed by the District.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;101(7)">(7)</span> "Health insurer" means any person that provides one or more health benefit plans or insurance in the District, including an insurer, a hospital and medical services corporation, a fraternal benefit society, a health maintenance organization, a multiple employer welfare arrangement, or any other person providing a plan of health insurance subject to the authority of the Commissioner of DISB.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;101(8)">(8)</span> "Hospital" means a facility that provides 24-hour inpatient care, including diagnostic, therapeutic, and other health-related services, for a variety of physical or mental conditions, and may, in addition, provide outpatient services, particularly emergency care.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;101(9)">(9)</span> "In-network health care provider" means the health care providers or health care facilities that have contracted with a health insurer to provide services to plan members for negotiated rates.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;101(10)">(10)</span> "Opioid use disorder" means a pattern of opioid use leading to clinically significant impairment or distress, as manifested by symptoms identified in the most recent publication of the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;101(11)">(11)</span> "Opioid use disorder treatment medication" means all medications approved by the United States Food and Drug Administration for the treatment of opioid use disorders.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;101(12)">(12)</span> "Prescriber" means a person who is licensed, registered, or otherwise authorized by the District to prescribe and administer prescription drugs in the course of a professional practice.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;101(13)">(13)</span> "Telehealth" means the delivery of healthcare services through interactive audio, video, or other electronic media used for the purpose of diagnosis, consultation, or treatment; provided, that services delivered through audio-only telephones, electronic mail messages, or facsimile transmissions are not included.</p>
            <p class="marginalia">New § 7-3202</p>
            <p id="&#xA7;102"><span class="level-num">Sec. 102. </span>Expanding access to opioid use disorder treatment.</p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;102(a)">(a)</span><span class="level-num" id="&#xA7;102(a)(1)">(1)</span> By January 1, 2020, each health insurer shall:</p>
            <p class="text-indent-3"><span class="level-num" id="&#xA7;102(a)(1)(A)">(A)</span> Create a list of its in-network health care providers that treat opioid use disorder, including the in-network health provider's contact information and an indication of whether the in-network health care provider has been certified by the United States Drug Enforcement Agency to prescribe opioid use disorder treatment medication; and</p>
            <p class="text-indent-3"><span class="level-num" id="&#xA7;102(a)(1)(B)">(B)</span> Maintain at least one in-network health care provider who is accepting new patients and is authorized to treat opioid use disorder, including through the use of opioid use disorder treatment medication. Services delivered through telehealth may satisfy the requirement of this subparagraph.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;102(a)(2)">(2)</span> Each health insurer shall update the list required by paragraph (1)(A) of this subsection on a quarterly basis.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;102(a)(3)">(3)</span><span class="level-num" id="&#xA7;102(a)(3)(A)">(A)</span> Upon the request of a beneficiary or prospective beneficiary of a health insurer, the health insurer shall transmit the list created and updated pursuant to paragraph (1) of this subsection to that beneficiary or prospective beneficiary by mail or by electronic means within 7 days after the receipt of the request.</p>
            <p class="text-indent-3"><span class="level-num" id="&#xA7;102(a)(3)(B)">(B)</span> Each health insurer shall publish the list and instructions on how to access the list created and updated pursuant to paragraphs (1) and (2) of this subsection on its website.</p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;102(b)">(b)</span> By January 1, 2020, and annually thereafter:</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;102(b)(1)">(1)</span> Each health insurer shall submit a report to DBH, DHCF, DISB, and the Council that includes the following:</p>
            <p class="text-indent-3"><span class="level-num" id="&#xA7;102(b)(1)(A)">(A)</span> A list of the health insurer's in-network health care providers that are certified by the United States Drug Enforcement Agency to prescribe opioid use disorder treatment medications, and which type of opioid use disorder treatment medications the health care providers prescribe;</p>
            <p class="text-indent-3"><span class="level-num" id="&#xA7;102(b)(1)(B)">(B)</span> The number of beneficiaries that were treated for opioid use disorder in the prior fiscal year; and</p>
            <p class="text-indent-3"><span class="level-num" id="&#xA7;102(b)(1)(C)">(C)</span> A description of any efforts by the health insurer in the prior fiscal year to ensure that its in-network capacity to treat opioid use disorder meets the needs of its beneficiaries.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;102(b)(2)">(2)</span> The Mayor shall submit a report to the Council that includes:</p>
            <p class="text-indent-3"><span class="level-num" id="&#xA7;102(b)(2)(A)">(A)</span> An analysis of programs in other jurisdictions that have sought to expand access to opioid use disorder treatment medications;</p>
            <p class="text-indent-3"><span class="level-num" id="&#xA7;102(b)(2)(B)">(B)</span> An evaluation of District health care providers' treatment capacity for opioid use disorders in the District, including opportunities for expanding and improving offerings;</p>
            <p class="text-indent-3"><span class="level-num" id="&#xA7;102(b)(2)(C)">(C)</span> An identification of any barriers to expanding access to additional opioid use disorder treatment medications;</p>
            <p class="text-indent-3"><span class="level-num" id="&#xA7;102(b)(2)(D)">(D)</span> An assessment of the financial costs associated with different methods of treating opioid use disorder;</p>
            <p class="text-indent-3"><span class="level-num" id="&#xA7;102(b)(2)(E)">(E)</span> An assessment of the current reimbursement rates for health care providers for opioid use disorder treatment; and</p>
            <p class="text-indent-3"><span class="level-num" id="&#xA7;102(b)(2)(F)">(F)</span> An identification and analysis of any gaps in opioid use disorder treatment options in the District.</p>
            <p class="marginalia">New § 7-3203</p>
            <p id="&#xA7;103"><span class="level-num">Sec. 103. </span>Hospital protocols for opioid use disorder.</p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;103(a)">(a)</span> By October 1, 2019, and annually thereafter, each hospital shall develop protocols governing the identification, treatment, discharge, and referral of patients with opioid use disorder, and submit the protocols to DOH.</p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;103(b)">(b)</span> By June 1, 2020, and annually thereafter, DOH shall submit an analysis of the sufficiency of each hospital's protocols to the chairperson of the Council committee with jurisdiction over matters related to health.</p>
            <p class="marginalia">New § 7-3204</p>
            <p id="&#xA7;104"><span class="level-num">Sec. 104. </span>DOC treatment of inmates with opioid use disorder.</p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;104(a)">(a)</span> An individual charged with treating DOC inmates for opioid use disorder shall be certified in the treatment of opioid use disorder by the American Society of Addiction Medicine, the American Academy of Addiction Psychiatry, the American Medical Association, the American Osteopathic Association, the American Psychiatric Association, or any other organization that the Director of DOH determines is appropriate. The requirements for certification in the treatment of opioid use disorder may be completed in a classroom setting or through online instruction.</p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;104(b)">(b)</span> DOC, in consultation with DOH, shall ensure that all opioid use disorder treatment medications are administered to inmates:</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;104(b)(1)">(1)</span> In the manner in which the medication was prescribed; and</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;104(b)(2)">(2)</span> For the entirety of the time an inmate is in DOC's custody, unless an individual charged with treating DOC inmates for opioid use disorder determines otherwise, in their clinical judgment, based on the specific inmate's treatment plan, or if an inmate is awaiting designation to Federal Bureau of Prisons custody.</p>
            <p class="marginalia">New § 7-3205</p>
            <p id="&#xA7;105"><span class="level-num">Sec. 105. </span>Rules.</p>
            <p>The Mayor, pursuant to <code-cite doc="D.C. Code" path="2|5|I">Title I of the District of Columbia Administrative Procedure Act, approved October 21, 1968 (82 Stat. 1204; D.C. Official Code § 2-501 <em>et seq</em>.)</code-cite>, may issue rules to implement the provisions of <code-cite doc="D.C. Code" path="7|32">this title</code-cite>.</p>
            <h1>TITLE II. SAFE ACCESS</h1>
            <p id="&#xA7;201"><span class="level-num">Sec. 201. </span>Title 25 of the District of Columbia Official Code is amended as follows:</p>
            <p class="marginalia">Amend <a href="/dc/council/code/sections/25-335.html">§ 25-335</a></p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;201(a)">(a)</span> Section 25-335 is amended as follows:</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;201(a)(1)">(1)</span> The existing text is designated as subsection (a).</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;201(a)(2)">(2)</span> The newly designated subsection (a)(2) is amended by striking the phrase "possession or" and inserting the phrase "the possession, other than for personal use, or" in its place.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;201(a)(3)">(3)</span> A new subsection (b) to read as follows:</p>
            <p class="text-indent-2">"<span class="level-num" id="">(b)</span> For the purposes of this section, the term "personal use" means the possession of drug paraphernalia in circumstances where there is no evidence of an intent to distribute or manufacture a controlled substance.".</p>
            <p class="marginalia">Amend <a href="/dc/council/code/sections/25-822.html">§ 25-822</a></p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;201(b)">(b)</span> Section 25-822 is amended as follows:</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;201(b)(1)">(1)</span> The existing text is designated as subsection (a).</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;201(b)(2)">(2)</span> The newly designated subsection (a)(2) is amended by striking the phrase "possession or" and inserting the phrase "possession, other than for personal use, or" in its place.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;201(b)(3)">(3)</span> A new subsection (b) to read as follows:</p>
            <p class="text-indent-2">"<span class="level-num" id="">(b)</span> For the purposes of this section, the term "personal use" means the possession of drug paraphernalia in circumstances where there is no evidence of an intent to distribute or manufacture a controlled substance.".</p>
            <p class="marginalia">Amend <a href="/dc/council/code/sections/47-2844.html">§ 47-2844</a></p>
            <p id="&#xA7;202"><span class="level-num">Sec. 202. </span>Section 47-2844(a-1)(1)(B) of the District of Columbia Official Code is amended by striking the phrase "possession, sale" and inserting the phrase "possession, other than for personal use, sale" in its place.</p>
            <p id="&#xA7;203"><span class="level-num">Sec. 203. </span>The Drug Paraphernalia Act of 1982, effective September 17, 1982 (D.C. Law 4-149; D.C. Official Code § 48-1101 <em>et seq.</em>), is amended as follows:</p>
            <p class="marginalia">Amend <a href="/dc/council/code/sections/48-1103.html">§ 48-1103</a></p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;203(a)">(a)</span> Section 4 (D.C. Official Code § 48-1103) is amended as follows:</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;203(a)(1)">(1)</span> Subsection (a) is amended by adding a new paragraph (1A) to read as follows:</p>
            <p class="text-indent-2">"<span class="level-num" id="">(1A)</span><span class="level-num" id="">(A)</span> Notwithstanding paragraph (1) of this subsection, it shall not be unlawful for a person to use, or possess with the intent to use, the materials described in <code-cite doc="D.C. Code" path="&#xA7;48-1101|(3)|(D)">section 2(3)(D)</code-cite> for the purpose of testing personal use quantities of a controlled substance.</p>
            <p class="text-indent-3">"<span class="level-num" id="">(B)</span> For the purposes of this paragraph, the term "personal use quantities" means possession of a controlled substance in circumstances where there is no other evidence of an intent to distribute, or to facilitate the manufacturing, compounding, processing, delivering, importing, or exporting of any controlled substance.".</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;203(a)(2)">(2)</span> Subsection (b) is amended by adding a new paragraph (1A) to read as follows:</p>
            <p class="text-indent-2">"<span class="level-num" id="">(1A)</span> Notwithstanding paragraph (1) of this subsection, it shall not be unlawful for a community-based organization, as that term is defined in <code-cite doc="D.C. Code" path="&#xA7;7-404|(a)|(1)">section 4(a)(1) of An Act To relieve physicians of liability for negligent medical treatment at the scene of an accident in the District of Columbia, effective February 18, 2017 (D.C. Law 21-186; D.C. Official Code § 7-404(a)(1))</code-cite>, to deliver or sell, or possess with intent to deliver or sell, the materials described in <code-cite doc="D.C. Code" path="&#xA7;48-1101|(3)|(D)">section 2(3)(D)</code-cite>.".</p>
            <p class="marginalia">Amend <a href="/dc/council/code/sections/48-1104.html">§ 48-1104</a></p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;203(b)">(b)</span> Section 5 (D.C. Official Code § 48-1104) is amended as follows:</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;203(b)(1)">(1)</span> The existing text is designated as subsection (a).</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;203(b)(2)">(2)</span> The newly designated subsection (a)(2) is amended by striking the phrase "use, dispensing, or possession" and inserting the phrase "use (other than for personal use), dispensing, or possession (other than for personal use)" in its place.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;203(b)(3)">(3)</span> A new subsection (b) to read as follows:</p>
            <p class="text-indent-2">"<span class="level-num" id="">(b)</span> For the purposes of this section, the term "personal use" means the use or possession of drug paraphernalia in circumstances where there is no evidence of an intent to distribute or manufacture a controlled substance.".</p>
            <p class="marginalia">Amend <a href="/dc/council/code/sections/48-1121.html">§ 48-1121</a></p>
            <p id="&#xA7;204"><span class="level-num">Sec. 204. </span>Section 150(a) of the District of Columbia Appropriations Act of 2001, approved November 22, 2000 (114 Stat. 2440; D.C. Official Code § 48-1121(a)), is repealed.</p>
            <p class="marginalia">Amend <a href="/dc/council/code/sections/7-1671.06.html">§ 7-1671.06</a></p>
            <p id="&#xA7;205"><span class="level-num">Sec. 205. </span>Section 7(g-2) of the Legalization of Marijuana for Medical Treatment Initiative of 1999, effective July 27, 2010 (D.C. Law 18-210; D.C. Official Code § 7-1671.06(g-2)), is amended to read as follows:</p>
            <p class="text-indent-1">"<span class="level-num" id="">(g-2)</span> A dispensary, cultivation center, or testing laboratory may be permitted to relocate to any election ward upon approval from the Mayor; provided, that no more than 2 dispensaries and 6 cultivation centers may be registered to operate within an election ward.".</p>
            <h1>TITLE III. SUBSTANCE ABUSE AND OPIOID OVERDOSE PREVENTION</h1>
            <p class="marginalia">Amend <a href="/dc/council/code/sections/7-404.html">§ 7-404</a></p>
            <p id="&#xA7;301"><span class="level-num">Sec. 301. </span>Section 4 of An Act To relieve physicians of liability for negligent medical treatment at the scene of an accident in the District of Columbia, approved November 8, 1965 (79 Stat. 1302; D.C. Official Code § 7-404), is amended as follows:</p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;301(a)">(a)</span> Subsection (a)(2) is amended by striking the period and inserting the phrase "practicing within the scope of practice for his or her profession." in its place.</p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;301(b)">(b)</span> A new subsection (b-1) is added to read as follows:</p>
            <p class="text-indent-1">"<span class="level-num" id="">(b-1)</span> An opioid antagonist issued in accordance with subsection (b) of this section shall be regarded as being issued for a legitimate medical purpose in the usual course of professional practice.".</p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;301(c)">(c)</span> Subsection (d)(1)(A) is amended to read as follows:</p>
            <p class="text-indent-1">"<span class="level-num" id="">(A)</span> A pharmacist may dispense or distribute, but not prescribe, an opioid antagonist pursuant to a written protocol and standing order.".</p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;301(d)">(d)</span> New subsections (f-1) and (f-2) are added to read as follows:</p>
            <p class="text-indent-1">"<span class="level-num" id="">(f-1)</span><span class="level-num" id="">(A)</span> Nothing in this section shall be construed to require a health care professional to prescribe, dispense, or distribute an opioid antagonist to a person at risk of experiencing an opioid related overdose or a family member, or friend, or other person in a position to assist a person at risk of experiencing an opioid related overdose, or an employee or volunteer of a community based organization.</p>
            <p class="text-indent-3">"<span class="level-num" id="">(B)</span> A health care professional that does not prescribe, dispense, or distribute an opioid antagonist based upon his or her professional judgment shall be immune from civil or criminal liability, unless the health care professional's decision not to prescribe, dispense, or distribute an opioid antagonist constitutes recklessness, gross negligence, or intentional misconduct.</p>
            <p class="text-indent-1">"<span class="level-num" id="">(f-2)</span> Nothing in this section shall be construed to expand the scope of practice of a health care professional.".</p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;301(e)">(e)</span> Subsection (g) is amended by striking the phrase "February 18, 2017" and inserting the phrase "the effective date of the Opioid Overdose Treatment and Prevention Omnibus Act of 2018, passed on 2nd reading on December 18, 2018 (Enrolled version of Bill 22-459)" in its place.</p>
            <h1>TITLE IV. PRESCRIPTION DRUG MONITORING PROGRAM</h1>
            <p id="&#xA7;401"><span class="level-num">Sec. 401. </span>The Prescription Drug Monitoring Program Act of 2013, effective February 22, 2014 (D.C. Law 20-66; D.C. Official Code § 48-853.01 <em>et seq.</em>), is amended as follows:</p>
            <p class="marginalia">New § 48-853.03a</p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;401(a)">(a)</span> A new section 4a is added to read as follows:</p>
            <p id="">"<span class="level-num">Sec. 4a. </span>Registration requirement for prescribers and dispensers.</p>
            <p class="text-indent-1">"<span class="level-num" id="">(a)</span> Any prescriber who is currently licensed, or becomes licensed before March 31, 2019, in the District to prescribe a controlled substance or other covered substance in the course of his or her professional practice, and any dispenser who is currently licensed, or becomes licensed before March 31, 2019, in the District to dispense a controlled substance or other covered substance to an ultimate user or his or her agent shall register with the Program by March 31, 2019.".</p>
            <p class="marginalia">Amend <a href="/dc/council/code/sections/48-853.04.html">§ 48-853.04</a></p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;401(b)">(b)</span> Section 5 (D.C. Official Code § 48-853.04) is amended as follows:</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;401(b)(1)">(1)</span> Designate the existing text as subsection (a).</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;401(b)(2)">(2)</span> New subsections (b) and (c) are added to read as follows:</p>
            <p class="text-indent-2">"<span class="level-num" id="">(b)</span> No prescriber or dispenser shall provide false or misleading information to the Department with the intent to obtain unauthorized access to, or alter the information in the possession of the Program.</p>
            <p class="text-indent-2">"<span class="level-num" id="">(c)</span> A violation of subsection (b) of this section shall constitute grounds for:</p>
            <p class="text-indent-3">"<span class="level-num" id="">(1)</span> The revocation, suspension, or denial of a District controlled substances registration;</p>
            <p class="text-indent-3">"<span class="level-num" id="">(2)</span> Disciplinary action by the relevant health occupations board pursuant to <code-cite doc="D.C. Code" path="&#xA7;3-1205.14|(c)">section 514(c) of the District of Columbia Health Occupations Revision Act of 1985, effective March 25, 1986 (D.C. Law 6-99; D.C. Official Code § 3-1205.14(c))</code-cite>; and</p>
            <p class="text-indent-3">"<span class="level-num" id="">(3)</span> The imposition of civil fines pursuant to <code-cite doc="D.C. Code" path="&#xA7;2-1801.04">section 104 of the Department of Consumer and Regulatory Affairs Civil Infractions Act of 1985, effective October 5, 1985 (D.C. Law 6-42; D.C. Official Code § 2-1801.04)</code-cite>.".</p>
            <p class="marginalia">Amend <a href="/dc/council/code/sections/48-853.05.html">§ 48-853.05</a></p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;401(c)">(c)</span> Section 6(b)(5) (D.C. Official Code § 48-853.05(b)(5)) is amended to read as follows:</p>
            <p class="text-indent-1">"<span class="level-num" id="">(5)</span> A specific investigation of a specific patient or of a specific dispenser or prescriber to an agent of a federal law-enforcement agency with authority to conduct drug diversion investigations.".</p>
            <p class="marginalia">Amend <a href="/dc/council/code/sections/48-853.07.html">§ 48-853.07</a></p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;401(d)">(d)</span> Section 8 (D.C. Official Code § 48-853.07) is amended as follows:</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;401(d)(1)">(1)</span> Subsection (a) is amended as follows:</p>
            <p class="text-indent-3"><span class="level-num" id="&#xA7;401(d)(1)(A)">(A)</span> Paragraph (1) is amended by striking the phrase "misuse; and" and inserting the phrase "misuse or abuse of covered substances;" in its place.</p>
            <p class="text-indent-3"><span class="level-num" id="&#xA7;401(d)(1)(B)">(B)</span> Paragraph (2) is amended by striking the phrase "misuse." and inserting the phrase "misuse or abuse of covered substances;" in its place.</p>
            <p class="text-indent-3"><span class="level-num" id="&#xA7;401(d)(1)(C)">(C)</span> New paragraphs (3) and (4) are added to read as follows:</p>
            <p class="text-indent-3">"<span class="level-num" id="">(3)</span> Criteria for indications of a possible violation of law or a possible breach of professional standards by a prescriber or dispenser; and</p>
            <p class="text-indent-3">"<span class="level-num" id="">(4)</span> A method for analysis of data collected by the Program using the criteria for indications of a possible violation of law or a possible breach of professional standards by a prescriber or dispenser.".</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;401(d)(2)">(2)</span> Subsection (b) is amended to read as follows:</p>
            <p class="text-indent-2">"<span class="level-num" id="">(b)</span><span class="level-num" id="">(1)</span> Upon the development of the criteria and data analysis, the Program may review prescription monitoring program data for indications of:</p>
            <p class="text-indent-4">"<span class="level-num" id="">(A)</span> Possible misuse or abuse of a covered prescription drug; and</p>
            <p class="text-indent-4">"<span class="level-num" id="">(B)</span> A possible violation of law or possible breach of professional standards by a prescriber or a dispenser.</p>
            <p class="text-indent-3">"<span class="level-num" id="">(2)</span> If the Program's review of prescription monitoring data indicates a possible violation of paragraph (1) of this subsection, the Director may, in addition to any discretionary disclosure of information pursuant to <code-cite doc="D.C. Code" path="48|8G">this act</code-cite>:</p>
            <p class="text-indent-4">"<span class="level-num" id="">(A)</span> Report the possible misuse or abuse by a patient to the specific prescriber or dispenser of the covered prescription drug for the purpose of intervention to prevent such misuse or abuse;</p>
            <p class="text-indent-4">"<span class="level-num" id="">(B)</span> Notify the prescriber or dispenser of the possible violation of law or possible breach of professional standards; and</p>
            <p class="text-indent-4">"<span class="level-num" id="">(C)</span> Provide education to the prescriber or dispenser.".</p>
            <h1>TITLE V. APPLICABILITY; FISCAL IMPACT STATEMENT; EFFECTIVE DATE</h1>
            <p class="marginalia">Amend § 7-3202</p>
            <p id="&#xA7;501"><span class="level-num">Sec. 501. </span>Applicability.</p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;501(a)">(a)</span> Section 102(b)(2) shall apply upon the date of inclusion of its fiscal effect in an approved budget and financial plan.</p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;501(b)">(b)</span> The Chief Financial Officer shall certify the date of the inclusion of the fiscal effect in an approved budget and financial plan and provide notice to the Budget Director of the Council of the certification.</p>
            <p class="text-indent-1"><span class="level-num" id="&#xA7;501(c)">(c)</span><span class="level-num" id="&#xA7;501(c)(1)">(1)</span> The Budget Director shall cause the notice of the certification to be published in the District of Columbia Register.</p>
            <p class="text-indent-2"><span class="level-num" id="&#xA7;501(c)(2)">(2)</span> The date of publication of the notice of the certification shall not affect the applicability of section 102(b)(2).</p>
            <p id="&#xA7;502"><span class="level-num">Sec. 502. </span>Fiscal impact statement.</p>
            <p>The Council adopts the fiscal impact statement in the committee report as the fiscal impact statement required by section 4a of the General Legislative Procedures Act of 1975, approved October 16, 2006 (120 Stat. 2038; D.C. Official Code § 1-301.47a).</p>
            <p id="&#xA7;503"><span class="level-num">Sec. 503. </span>Effective date.</p>
            <p>This act shall take effect following approval by the Mayor (or in the event of veto by the Mayor, action by the Council to override the veto), a 30-day period of congressional review as provided in section 602(c)(1) of the District of Columbia Home Rule Act, approved December 24, 1973 (87 Stat. 813; D.C. Official Code § 1-206.02(c)(1)), and publication in the District of Columbia Register.</p>
          </section>
        </section>
      </div>
    </main>
    <footer>
      <section class="container center">
        <p>The codes and laws on this website are in the public domain.</p>
        <p>
              Please do not scrape. Instead, bulk download the <a href="https://github.com/dccouncil/dc-law-html">HTML</a> or <a href="https://github.com/dccouncil/dc-law-xml">XML</a>.
            </p>
        <p>Powered by the non-profit <a href="http://www.openlawlib.org/">Open Law Library</a>.</p>
      </section>
    </footer>
    <script type="text/javascript" src="/js/main.js"> </script>
  </body>
</html>
